References
- Selinger CP, Robinson A, Leong RW. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opin Drug Saf 2011;10:863-70
- Jackson CA, Clatworthy J, Robinson A, et al. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010;105:525-39
- Selinger C, Eaden J, Jones B, et al. Modifiable Factors Associated With Nonadherence To Maintenance medication for Inflammatory Bowel Disease. Inflamm Bowel Dis 2013;19:2199-206
- Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53:1020-4
- Kane SV, Chao J, Mulani PM. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients. Adv Ther 2009;26:936-46
- Feagan B, Kozma C, Slaton T, et al. Health care costs for Crohn’s Disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence. J Med Econ 2014, published online 27 Aug 2014. [Epub ahead of print]
- Selinger CP, Kemp A, Leong RW. Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia. Expert Rev Gastroenterol Hepatol 2014;8:329-34
- Kane S, Dixon L. Adherence rates with infliximab therapy in Crohn’s disease. Aliment Pharmacol Ther 2006;24:1099-103
- Carter CT, Waters HC, Smith DB. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease. Patient Prefer Adherence 2012;6:417-26
- Carter CT, Waters HC, Smith DB. Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs. Adv Ther 2011;28:671-83